Fig. 1 · Structure

Documents & Downloads

CHIR-98014

Cat. No. A11085 CAS 252935-94-7

GSK-3 inhibitor

CHIR-98014 is a very potent, selective, cell-permeable reversible inhibitor of GSK-3.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
GSK-3β IC50 0.58nM
GSK-3α IC50 0.65nM
p70S6K IC50 >1μM
c-Src IC50 >1μM
bFGFR IC50 >1μM
KDR IC50 >2μM
IGF-1R IC50 >2μM
InsulinReceptor IC50 >2μM
Cdc2 IC50 3.7μM
Akt1 IC50 >5μM
Tie-2 IC50 >5μM
FLT1 IC50 >5μM
CK1ε IC50 >5μM
ERK2 IC50 >10μM
PKCα IC50 >10μM
p90RSK2 IC50 >10μM
Chk1 IC50 >10μM
DNA-PK IC50 >10μM
PI3K IC50 >10μM

19 targets · Scroll to view more

In Vitro Studies

In ES-D3 cells, CHIR-98014 at 1 μM significantly induced T gene expression, assessed by qPCR. In Huh-7 cells, CHIR-98014 alone at 50 nM for 48 h notably reduced GSK3B-protein levels. In a separate ES-D3 viability study, CHIR-98014 reduced viability by 52% at 1 μM and had an IC50 of 1.1 μM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

T Gene Expression in Embryonic Stem Cells

Cell-based study · ES-D3 cells [1]

ES-D3 cells treated with CHIR-98014 at 1 μM showed significant induction of T gene expression, assessed by qPCR.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
qPCR analysis of TT gene expression 1 μM CHIR-98014; after three days of differentiation: up to 2,500-fold; scaling to undifferentiated ES cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
six days of treatment
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: CHIR-98014

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Changes in gene expression during differentiation and incubation with GSK3 inhibitors (S68, S70, S72); Figure 3 legend (S98, S100, S101)

qPCR analysis of T: qPCR analysis of T; comparator: randomly differentiated ES cells of the same day — Results > Changes in gene expression during differentiation and incubation with GSK3 inhibitors (S68, S70, S72); Figure 3 legend (S98, S100)

Protein expression in hepatoma cells

Cell-based study · Huh-7; N = 3 (biologic replicates) [2]

Huh-7 cells were treated with CHIR-98014 at 50 nM for 48 h. Western blot analysis showed that GSK3B protein levels were notably restrained by β-Sitosterol or CHIR-98014 treatment alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GSK3B-protein level by Western blotReported result GSK3B-protein level was notably restrained by β-Sitosterol or CHIR-98014 treatment alone[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 nM
Exposure duration
48 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: CHIR-98014

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Comparison of the effects of β-Sitosterol and GSK-3 inhibitor on cell proliferation, invasion and apoptosis of hepatocellular carcinoma cells (S126, S131, S133)

GSK3B-protein level by Western blot: GSK3B-protein level by Western blot; comparator: control group — Results > Comparison of the effects of β-Sitosterol and GSK-3 inhibitor on cell proliferation, invasion and apoptosis of hepatocellular carcinoma cells (S126, S131)

Viability of mouse embryonic stem cells

Cell-based study · mouse embryonic stem cell line ES-D3 [1]

Mouse ES-D3 embryonic stem cells received CHIR-98014 in medium devoid of LIF and with reduced serum, with viability assessed by MTT assay. CHIR-98014 reduced viability by 52% at 1 μM, showed increasing toxicity with increasing concentrations, and had an IC50 of 1.1 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was measured with the MTT assay.IC50 IC50 of CHIR-98014 was 1.1 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 – 10 μM
Exposure duration
three day treatment
Method
medium devoid of LIF and with reduced serum
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: CHIR-98014

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cell viability assay (S16); Results > Cell viability (S51, S52); Figure 1 legend (S85, S86, S87)

Cell viability was measured with the MTT assay.: Cell viability was measured with the MTT assay.; comparator: DMSO without inhibitors — Results > Cell viability (S51, S52); Figure 1 legend (S86)

In Vivo Studies

Female NSG mice injected with KMT2A-r B-ALL PDX cells received CHIR-98014 at 15 mg/kg by oral gavage once daily. From 5 wk, peripheral blood human CD45+ cell measurements showed comparable leukemia cell expansion between vehicle and CHIR-98014-alone groups. [3]

Leukemia cell expansion in a xenograft model

Animal study · KMT2A-r B-ALL PDX cells were injected into female NSG mice between 8 and 12 wk of age [3]

Female NSG mice injected with KMT2A-r B-ALL PDX cells received CHIR-98014 at 15 mg/kg by oral gavage once daily. From 5 wk, leukemia cell expansion was comparable between vehicle and CHIR-98014-alone groups, assessed by peripheral blood human CD45+ cell percentages.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage of human CD45+ cells in the peripheral bloodReported result Starting from 5 wk, we observed comparable leukemia cell expansion between vehicle and CHIR98014-alone groups[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
once daily
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CHIR-98014 15 mg/kgvehicleStarting from 5 wk, we observed comparable leukemia cell expansion between vehicle and CHIR98014-alone groups[3]
CHIR-98014 15 mg/kg
Model: KMT2A-r B-ALL PDX cells were injected into female NSG mice between 8 and 12 wk of age
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: CHIR-98014

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Combination Therapy Using GSK3i and BETi to Treat PDXs In Vivo. (S85, S86); Methods > In Vivo Competition Assay and Drug Efficacy Evaluations. (S136, S139)

percentage of human CD45+ cells in the peripheral blood: percentage of human CD45+ cells in the peripheral blood; comparator: vehicle — Results > Combination Therapy Using GSK3i and BETi to Treat PDXs In Vivo. (S85, S86)

CHIR-98014 15 mg/kg · Results > Combination Therapy Using GSK3i and BETi to Treat PDXs In Vivo. (S86); Methods > In Vivo Competition Assay and Drug Efficacy Evaluations. (S139)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 252935-94-7
Applications GSK-3 inhibitor
Formula C20H17Cl2N9O2
Molecular Weight 486.3
SMILES
C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2N3C=CN=C3)NCCNC4=NC(=C(C=C4)[N+](=O)[O-])N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 7 mg/mL (14.39 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
5% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Naujok O, Lentes J, Diekmann U, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC Res Notes (2014). PMID: 24779365 DOI: 10.1186/1756-0500-7-273 Source material
  2. [2] Wang R, Tang D, Ou L, et al. β-Sitosterol alleviates the malignant phenotype of hepatocellular carcinoma cells via inhibiting GSK3B expression. Hum Cell (2024). PMID: 38814517 DOI: 10.1007/s13577-024-01081-y Source material
  3. [3] Wright S, Hu J, Wang H, et al. Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. Proc Natl Acad Sci U S A (2023). PMID: 37036970 DOI: 10.1073/pnas.2220134120 Source material

Added to your cart

View Cart Checkout
Loading...